Zoetis Inc. (NYSE:ZTS) Position Maintained by Vigilant Capital Management LLC
Vigilant Capital Management LLC maintained its position in shares of Zoetis Inc. (NYSE:ZTS) during the second quarter, Holdings Channel reports. The institutional investor owned 1,673 shares of the company’s stock at the end of the second quarter. Vigilant Capital Management LLC’s holdings in Zoetis were worth $104,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. BlackRock Inc. increased its position in Zoetis by 2,471.1% in the first quarter. BlackRock Inc. now owns 36,082,470 shares of the company’s stock worth $1,925,722,000 after buying an additional 34,679,064 shares during the last quarter. Vanguard Group Inc. increased its position in Zoetis by 1.7% in the first quarter. Vanguard Group Inc. now owns 32,744,421 shares of the company’s stock worth $1,747,570,000 after buying an additional 546,287 shares during the last quarter. State Street Corp increased its position in Zoetis by 4.9% in the first quarter. State Street Corp now owns 21,256,557 shares of the company’s stock worth $1,134,453,000 after buying an additional 986,680 shares during the last quarter. Morgan Stanley increased its position in Zoetis by 182.5% in the first quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock worth $780,119,000 after buying an additional 9,442,207 shares during the last quarter. Finally, Clearbridge Investments LLC increased its position in Zoetis by 4.2% in the first quarter. Clearbridge Investments LLC now owns 9,254,662 shares of the company’s stock worth $493,921,000 after buying an additional 373,568 shares during the last quarter. 95.10% of the stock is currently owned by institutional investors.
Shares of Zoetis Inc. (ZTS) opened at 63.35 on Monday. The stock has a market capitalization of $31.09 billion, a PE ratio of 36.83 and a beta of 1.03. The company’s 50 day moving average price is $62.00 and its 200-day moving average price is $56.13. Zoetis Inc. has a 52 week low of $46.86 and a 52 week high of $63.85.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 4th. The company reported $0.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.05. Zoetis had a return on equity of 65.35% and a net margin of 17.25%. The firm had revenue of $1.23 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same period in the previous year, the firm posted $0.48 EPS. Zoetis’s revenue for the quarter was up 5.9% on a year-over-year basis. Equities research analysts predict that Zoetis Inc. will post $2.33 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Thursday, June 15th will be paid a dividend of $0.105 per share. The ex-dividend date of this dividend is Tuesday, June 13th. This represents a $0.42 annualized dividend and a yield of 0.66%. Zoetis’s payout ratio is 24.42%.
A number of equities analysts have recently issued reports on the company. Cowen and Company set a $60.00 price target on Zoetis and gave the stock a “buy” rating in a research report on Tuesday, July 11th. Zacks Investment Research downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Hilliard Lyons assumed coverage on Zoetis in a research report on Tuesday, June 20th. They set a “buy” rating and a $77.00 price target on the stock. Cantor Fitzgerald assumed coverage on Zoetis in a research report on Friday, June 16th. They set an “overweight” rating and a $75.00 price target on the stock. Finally, BMO Capital Markets downgraded Zoetis from an “outperform” rating to a “market perform” rating and increased their price target for the stock from $64.00 to $65.00 in a research report on Tuesday, June 13th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company’s stock. Zoetis currently has a consensus rating of “Buy” and a consensus price target of $62.42.
In other news, insider Catherine A. Knupp sold 5,785 shares of the company’s stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $60.16, for a total transaction of $348,025.60. Following the completion of the transaction, the insider now directly owns 24,415 shares of the company’s stock, valued at approximately $1,468,806.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.31% of the company’s stock.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.